Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Simultaneous Versus Staged Resection for Initially Resectable Synchronous Rectal Cancer Liver-limited Metastasis

Not Applicable

Completed

Conditions: Rectal Neoplasm With Metastasis to the Liver

Interventions: Procedure: simultaneous resection of liver metastasis and the rectal primary tumor
Procedure: staged resection of liver metastasis and the rectal primary tumor

First Posted Date: 2008-05-14

Last Posted Date: 2022-07-07

Lead Sponsor: Fudan University

Target Recruit Count: 180

Registration Number: NCT00677586

Clinical Trial on the Effectiveness of Herbal Medicinal Mixture in Parkinson Disease

Phase 2

Completed

Conditions: Parkinson's Disease

Interventions: Drug: Placebo
Drug: Herbal Medicinal Mixture (Roucongrong, Heshouwu etc.)

First Posted Date: 2008-04-11

Last Posted Date: 2011-03-22

Lead Sponsor: Fudan University

Target Recruit Count: 158

Registration Number: NCT00656253

Locations: 🇨🇳
Department of Neurology, Yueyang Hospital of Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, Shanghai, China
🇨🇳
Department of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
🇨🇳
The Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, Shanghai, China

and more 7 locations

Trial of Preoperative Hepatic and Regional Arterial Chemotherapy (PHRAC) to Prevent Postoperative Liver Metastasis of Colorectal Cancer

Phase 3

Conditions: Colorectal Neoplasms

Interventions: Procedure: Preoperative hepatic and regional arterial chemotherapy using oxaliplatin, MMC and FUDR
Procedure: surgery

First Posted Date: 2008-03-26

Last Posted Date: 2009-03-25

Lead Sponsor: Fudan University

Target Recruit Count: 600

Registration Number: NCT00643877

Locations: 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, China

Study of Apatinib as an Inhibitor of Tumor Angiogenesis

Phase 1

Conditions: Tumor

Interventions: Drug: apatinib

First Posted Date: 2008-03-12

Last Posted Date: 2008-07-22

Lead Sponsor: Fudan University

Target Recruit Count: 18

Registration Number: NCT00633490

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China

Sequential Versus Simultaneous Use of Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer (MBC)

Phase 2

Completed

Conditions: Breast Cancer
Metastasis, Neoplasm

Interventions: Drug: Vinorelbine and Capecitabine

First Posted Date: 2008-03-05

Last Posted Date: 2011-07-07

Lead Sponsor: Fudan University

Target Recruit Count: 60

Registration Number: NCT00629148

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, China

Clinical Trial on the Effectiveness of Traditional Chinese Medicinal Mixture in Parkinson Disease

Phase 2

Conditions: Parkinson Disease

Interventions: Drug: Traditional Chinese Medicinal Mixture (composed of Roucongrong and adjuvant)
Drug: placebo

First Posted Date: 2008-03-05

Last Posted Date: 2010-05-28

Lead Sponsor: Fudan University

Target Recruit Count: 144

Registration Number: NCT00629161

Locations: 🇨🇳
Department of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
🇨🇳
Zhongshan hospital, Fudan University, Shanghai, Shanghai, China
🇨🇳
Department of Neurology, Xuanwu hospital, Capital University of Medical Sciences, Beijing, Beijing, China

and more 7 locations

Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: gemcitabine and cisplatin

First Posted Date: 2008-01-25

Last Posted Date: 2011-07-04

Lead Sponsor: Fudan University

Target Recruit Count: 70

Registration Number: NCT00601159

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China

Epirubicin Cisplatin and Fluorouracil (FU) Combined With Endostar in Patients With Advanced or Metastatic Gastric Cancer

Phase 2

Completed

Conditions: Gastric Cancer

Interventions: Drug: ECF-endostar

First Posted Date: 2008-01-16

Last Posted Date: 2011-06-28

Lead Sponsor: Fudan University

Target Recruit Count: 25

Registration Number: NCT00595972

Locations: 🇨🇳
Fudan University Cancer Hospital, ShangHai, Shanghai, China

Sorafenib as a Second Line Treatment in Patients With Advanced or Metastatic Gastric Cancer

Phase 2

Terminated

Conditions: Gastric Cancer

Interventions: Drug: sorafenib

First Posted Date: 2008-01-16

Last Posted Date: 2009-07-07

Lead Sponsor: Fudan University

Target Recruit Count: 5

Registration Number: NCT00595985

Locations: 🇨🇳
Fudan University Cancer Hospital, ShangHai, Shanghai, China

An All-Oral Combination of Capecitabine and Cyclophosphamide in Patients With Metastatic Breast Cancer (MBC)

Phase 2

Conditions: Breast Cancer

Interventions: Drug: capecitabine and cyclophosphamide

First Posted Date: 2008-01-10

Last Posted Date: 2008-04-18

Lead Sponsor: Fudan University

Target Recruit Count: 60

Registration Number: NCT00589901

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy